158 related articles for article (PubMed ID: 30064682)
21. Localised intravascular coagulation complicating venous malformations: Clinical characterisation.
Blaise S; Soya E; Nou M; Malloizel-Delaunay J; Thiel H; Bisdorff-Bresson A; Seinturier C
Phlebology; 2024 Apr; 39(3):169-173. PubMed ID: 37978831
[TBL] [Abstract][Full Text] [Related]
22. Analysis and Treatment of Multiple Severe Venous Vascular Malformation Syndrome Combined with Coagulopathy.
Qiao JB; Li J; Zhang XF
Chin Med J (Engl); 2015 Sep; 128(18):2546-8. PubMed ID: 26365978
[No Abstract] [Full Text] [Related]
23. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
24. The discovery of dabigatran etexilate for the treatment of venous thrombosis.
Feuring M; van Ryn J
Expert Opin Drug Discov; 2016 Jul; 11(7):717-31. PubMed ID: 27159158
[TBL] [Abstract][Full Text] [Related]
25. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
26. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
Spannagl M; Bauersachs R; Debus ES; Gawaz M; Gerlach H; Haas S; Hach-Wunderle V; Lindhoff-Last E; Riess H; Schellong S; Schinzel H; Bode C
Hamostaseologie; 2012; 32(4):294-305. PubMed ID: 23114798
[TBL] [Abstract][Full Text] [Related]
27. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Fanola CL
Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
[TBL] [Abstract][Full Text] [Related]
28. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients.
Mazoyer E; Enjolras O; Bisdorff A; Perdu J; Wassef M; Drouet L
Arch Dermatol; 2008 Jul; 144(7):861-7. PubMed ID: 18645137
[TBL] [Abstract][Full Text] [Related]
29. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation.
Vandenbriele C; Vanassche T; Peetermans M; Verhamme P; Peerlinck K
J Thromb Thrombolysis; 2014 Jul; 38(1):121-3. PubMed ID: 24202701
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
[TBL] [Abstract][Full Text] [Related]
32. Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients.
Lagneaux E; Boon LM; Revencu N; Vikkula M; Hermans C
Res Pract Thromb Haemost; 2024 Mar; 8(3):102400. PubMed ID: 38738172
[TBL] [Abstract][Full Text] [Related]
33. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
34. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Maegdefessel L; Linde T; Krapiec F; Hamilton K; Steinseifer U; van Ryn J; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Res; 2010 Sep; 126(3):e196-200. PubMed ID: 20659761
[TBL] [Abstract][Full Text] [Related]
35. [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
Samama M; Conard J; Horellou MH; Le Flem L; Guinet C; Depasse F
Ann Pharm Fr; 2010 Nov; 68(6):359-69. PubMed ID: 21073994
[TBL] [Abstract][Full Text] [Related]
36. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
37. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
[TBL] [Abstract][Full Text] [Related]
38. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
39. Repeated Intracranial Hemorrhage After Delivery Induced by Coagulopathy Associated with Multiple Venous Malformations.
Tsukamoto E; Tanei T; Kato T; Naito T; Torii J; Ishii K; Hasegawa T
World Neurosurg; 2019 Aug; 128():434-437. PubMed ID: 31121372
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
Chen D; Wang S; Diao X; Zhu Q; Shen H; Han X; Wang Y; Gong G; Xu Y
Bioorg Med Chem; 2015 Dec; 23(23):7405-16. PubMed ID: 26537784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
